阿米卡星模型引导精准给药达标AUC的模拟研究
该模拟研究基于两个已验证的群体药代动力学模型构建3000例虚拟重症患者,评估贝叶斯预测下不同采血点估算阿米卡星稳态AUC的准确性。结果显示第1天2点采样(峰浓度3和4小时、谷浓度24小时)的达标概率高于1点采样,且与丰富采样相当,支持早期精准达标。
要点
- 第1天1点采样达标概率在23和15小时分别升至47.3%和94.4%。
- 第1天2点采样(峰3和4小时+谷24小时)达标概率达72.3%和99.5%。
- 第2、3天不同采样点数及eGFR下达标概率相当,2点采样优于1点采样。
核心结论
- 在重症患者中,第1天采用2点采样(峰浓度3和4小时、谷浓度24小时)的贝叶斯预测可更准确估算阿米卡星AUC并早期达标。
研究设计与样本
- 模拟研究,基于系统文献检索识别的2个已验证群体药代动力学模型生成3000例虚拟重症患者人群。
主要发现
- 第1天1点采样时,两个群体药代动力学模型的先验达标概率分别为26.3%和45.6%,在23和15小时分别升至47.3%和94.4%。
- 第1天2点采样(峰3和4小时、谷24小时)的达标概率分别进一步升至72.3%和99.5%。
- 第2、3天无论3或6个采样点及估算肾小球滤过率如何,达标概率相当。
- 第1天2点采样对阿米卡星AUC估算的预测准确性高于1点采样,且比丰富采样更合理。
关键数值与推荐
- 以稳态估算AUC/参考AUC比值在0.8-1.2范围内作为达标概率的评价标准。
临床怎么用
- 重症患者使用阿米卡星时,可考虑在第1天采用峰浓度(3和4小时)与谷浓度(24小时)的2点采样进行贝叶斯预测,以早期实现目标AUC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Amikacin requires therapeutic drug monitoring for optimum efficacy; however, the optimal model-informed precision dosing strategy for the area under the concentration-time curve (AUC) of amikacin is uncertain. This simulation study aimed to determine the efficient blood sampling points using the Bayesian forecasting approach for early achievement of the target AUC range for amikacin in critically ill patients. METHODS: We generated a virtual population of 3000 individuals using 2 validated population pharmacokinetic models identified using a systematic literature search. AUC for each blood sampling point was evaluated using the probability of achieving a ratio of estimated/reference AUC at steady state in the 0.8-1.2 range. RESULTS: On day 1, the 1-point samplings for population pharmacokinetic models showed a priori probabilities of 26.3 and 45.6%, which increased to 47.3 and 94.4% at 23 and 15 h, respectively. Using 2-point sampling at the peak (3 and 4 h) and trough (24 h) on day 1, these probabilities further increased to 72.3 and 99.5%, respectively. These probabilities were comparable on days 2 and 3, regardless of 3 and 6 sampling points or estimated glomerular filtration rate. These results indicated the higher predictive accuracy of 2-point sampling than 1-point sampling on day 1 for amikacin AUC estimation. Moreover, 2-point sampling was a more reasonable approach than rich sampling. CONCLUSIONS: This study contributes to the development of an efficient model-informed precision dosing strategy for early targeting of amikacin AUC in critically ill patients.
引用
- Yamada T, Oda K, Nishihara M, et al. A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. Br J Clin Pharmacol. 2024. PMID: 38304967. doi:10.1111/bcp.16002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。